Sirukumab Medicine 09 January 2018 Extended indication Moderately to severely active Rheumatoid Arthritis (RA), second or third line after DMARD and/or bDMARD (biologic), 2L, 3L. Therapeutic value No judgement Total cost Registration phase Unknown Product Active substance Sirukumab Domain Chronic immune diseases Reason of inclusion Main indication Rheumatism Extended indication Moderately to severely active Rheumatoid Arthritis (RA), second or third line after DMARD and/or bDMARD (biologic), 2L, 3L. Current proprietary name Already available biosimilars / generics Proprietary name Plivensia Manufacturer Janssen Portfolio holder Mechanism of action Unknown Route of administration Unknown Therapeutical formulation Unknown Budgetting framework Unknown Centre of expertise Additional remarks Registratieaanvraag ingetrokken in november 2017. Fabrikant geeft aan dat het een strategische beslissing betreft en dat alle studies zijn stopgezet. Registration Registration route Unknown Type of trajectory Unknown Particularity Unknown ATMP Unknown Submission date Expected Registration Orphan drug Unknown Registration phase Unknown Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks